Showing results (21-30 of 96) with videos related to
Sort By:
Pageof 10
Journal of Pediatric Gastroenterology and Nutrition|August 23, 2019
Engaging Patients and Caregivers in Research for Pediatric Inflammatory Bowel Disease: Top 10 Research PrioritiesAmy Grant, Melissa Crane, Andreas Laupacis, et al.American Journal of Medical Genetics. Part A|June 10, 2005
CDG-IL: an infant with a novel mutation in the ALG9 gene and additional phenotypic featuresMichael Weinstein, Els Schollen, Gert Matthijs, et al.Inflammatory Bowel Diseases|May 12, 2011
Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classificationArie Levine, Anne Griffiths, James Markowitz, et al.Journal of Crohn'S & Colitis|May 27, 2020
Appraisal of the PIBD-classes Criteria: A Multicentre ValidationOren Ledder, Micol Sonnino, Liron Birimberg-Schwartz, et al.Journal of Pediatric Gastroenterology and Nutrition|June 30, 2009
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACHWallace Crandall, Jeffrey Hyams, Subra Kugathasan, et al.Inflammatory Bowel Diseases|June 2, 2026
Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn's disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHANIdo Orlin, Balsam Younis, Marco Gasparetto, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2011
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitisJeffrey Hyams, Lakshmi Damaraju, Marion Blank, et al.Journal of Neonatal Surgery|October 27, 2015
Urinary Claudin-2 Measurements as a Predictor of Necrotizing Enterocolitis: A Pilot StudyBrian P Blackwood M D, Douglas R Wood B S, Carrie Y Yuan B S, et al.Gastroenterology|February 28, 2007
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in childrenJeffrey Hyams, Wallace Crandall, Subra Kugathasan, et al.Current Medical Research and Opinion|January 19, 2011
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extensionJeffrey Hyams, Thomas D Walters, Wallace Crandall, et al.Pageof 10